MHRA Inspection Prompts European Review Of US Firm's Drug Products

This article was originally published in The Gold Sheet

30 Jun 2016
News

Executive Summary

Pharmaceutics International must suspend manufacturing of commercial and investigational medicinal products largely for failure to manage cross-contamination risks appropriately, according to EU GMP non-compliance notice. Resumption of IMP production will hinge on approval of trial-by-trial risk assessments.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Europe

United Kingdom

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Europe

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS001002

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS001002

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

MHRA Inspection Prompts European Review Of US Firm's Drug Products

News

Executive Summary

Related Content

Enforcement Log, Dateline 09.30.16: Pan Drugs, Zhejiang Hisoar, Wockhardt, Zhejiang Bangli, Pharmaceutics International

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert